Literature DB >> 28913673

Multiple non-catalytic ADAMs are novel integrin α4 ligands.

Lei Wang1, Jason A Hoggard1, Erica D Korleski1, Gideon V Long2, Brandy C Ree2, Kenneth Hensley2, Stephen R Bond3, Tyra G Wolfsberg3, JianMing Chen1, Tonya N Zeczycki1, Lance C Bridges4,5.   

Abstract

The ADAM (a disintegrin and metalloprotease) protein family uniquely exhibits both catalytic and adhesive properties. In the well-defined process of ectodomain shedding, ADAMs transform latent, cell-bound substrates into soluble, biologically active derivatives to regulate a spectrum of normal and pathological processes. In contrast, the integrin ligand properties of ADAMs are not fully understood. Emerging models posit that ADAM-integrin interactions regulate shedding activity by localizing or sequestering the ADAM sheddase. Interestingly, 8 of the 21 human ADAMs are predicted to be catalytically inactive. Unlike their catalytically active counterparts, integrin recognition of these "dead" enzymes has not been largely reported. The present study delineates the integrin ligand properties of a group of non-catalytic ADAMs. Here we report that human ADAM11, ADAM23, and ADAM29 selectively support integrin α4-dependent cell adhesion. This is the first demonstration that the disintegrin-like domains of multiple catalytically inactive ADAMs are ligands for a select subset of integrin receptors that also recognize catalytically active ADAMs.

Entities:  

Keywords:  ADAM; Cell adhesion; Disintegrin; Integrin; Lymphocyte

Mesh:

Substances:

Year:  2017        PMID: 28913673     DOI: 10.1007/s11010-017-3190-y

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  39 in total

Review 1.  ADAMs: modulators of cell-cell and cell-matrix interactions.

Authors:  Judith M White
Journal:  Curr Opin Cell Biol       Date:  2003-10       Impact factor: 8.382

2.  The role of ADAM 15 in glomerular mesangial cell migration.

Authors:  John Martin; Lisa V Eynstone; Malcolm Davies; John D Williams; Robert Steadman
Journal:  J Biol Chem       Date:  2002-06-28       Impact factor: 5.157

Review 3.  Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: biological function and structure.

Authors:  Theo Klein; Rainer Bischoff
Journal:  J Proteome Res       Date:  2010-10-14       Impact factor: 4.466

4.  Selective modulation of integrin-mediated cell migration by distinct ADAM family members.

Authors:  Jing Huang; Lance C Bridges; Judith M White
Journal:  Mol Biol Cell       Date:  2005-08-03       Impact factor: 4.138

5.  Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates.

Authors:  Roma Stawikowska; Mare Cudic; Marc Giulianotti; Richard A Houghten; Gregg B Fields; Dmitriy Minond
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

Review 6.  What have snakes taught us about integrins?

Authors:  T F Huang
Journal:  Cell Mol Life Sci       Date:  1998-06       Impact factor: 9.261

Review 7.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

8.  TACE and other ADAM proteases as targets for drug discovery.

Authors:  M L. Moss; J M. White; M H. Lambert; R C. Andrews
Journal:  Drug Discov Today       Date:  2001-04-01       Impact factor: 7.851

9.  The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha4beta1.

Authors:  Lance C Bridges; Patricia H Tani; Krista R Hanson; Charles M Roberts; Matthew B Judkins; Ron D Bowditch
Journal:  J Biol Chem       Date:  2001-11-27       Impact factor: 5.157

10.  The cysteine-rich domain regulates ADAM protease function in vivo.

Authors:  Katherine M Smith; Alban Gaultier; Helene Cousin; Dominique Alfandari; Judith M White; Douglas W DeSimone
Journal:  J Cell Biol       Date:  2002-12-02       Impact factor: 10.539

View more
  4 in total

1.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

2.  A disintegrin and metalloprotease 23 hypermethylation predicts decreased disease-free survival in low-risk breast cancer patients.

Authors:  Iveta Zmetakova; Lenka Kalinkova; Bozena Smolkova; Viera Horvathova Kajabova; Zuzana Cierna; Ludovit Danihel; Martin Bohac; Tatiana Sedlackova; Gabriel Minarik; Marian Karaba; Juraj Benca; Marina Cihova; Verona Buocikova; Svetlana Miklikova; Michal Mego; Ivana Fridrichova
Journal:  Cancer Sci       Date:  2019-03-18       Impact factor: 6.716

3.  Decreased methylation in the SNAI2 and ADAM23 genes associated with de-differentiation and haematogenous dissemination in breast cancers.

Authors:  Lenka Kalinkova; Iveta Zmetakova; Bozena Smolkova; Gabriel Minarik; Tatiana Sedlackova; Viera Horvathova Kajabova; Zuzana Cierna; Michal Mego; Ivana Fridrichova
Journal:  BMC Cancer       Date:  2018-09-06       Impact factor: 4.430

4.  How tetraspanin-mediated cell entry of SARS-CoV-2 can dysregulate the shedding of the ACE2 receptor by ADAM17.

Authors:  Eamonn F Healy
Journal:  Biochem Biophys Res Commun       Date:  2022-01-15       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.